NCT05070728View on ClinicalTrials.gov

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions
UveitisUveitis, PosteriorUveitis, Intermediate
Interventions
DRUG

Sham Injector

Intravitreal sham injection

DRUG

FAI Insert

"Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle."

Trial Locations (1)

02451

EyePoint Study Site, Waltham

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT05070728 - Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert | Biotech Hunter | Biotech Hunter